• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Joint Statement to Change the Blood Donation Deferral Policy for MSM

November 21, 2014

200248868-001The Department of Health and Human Services Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) recommended changing the current lifetime blood donation deferral period for men who have had sex with men (MSM) to a one year deferral period.

The blood banking community does not support the FDA’s current lifetime deferral for MSM. The AABB, America’s Blood Centers, and the American Red Cross issued a joint statement supporting the committee’s recommendation which is in line with other activities that pose similar risks of transfusion-transmitted infections.

Reference

1. AABB Statement. Joint Statement on ACBTSA Recommendation to Change MSM Deferral Policy, November 2014. Accessed online November 18, 2014. http://www.aabb.org/advocacy/statements/Pages/statement141114.aspx

Filed Under

  • Blood Donation
  • News
  • Policy and Guidelines

Recommended

  • Thawed Plasma in Emergency Department Expedites Transfusion and May Benefit Trauma Patients

  • Zika Virus RNA Can Shed for More Than 6 Months in Semen from Some Infected Men

  • Storage Duration Affects Hematological and Metabolic Parameters in Patients with Sickle Cell Disease

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Pre-Hospital Resuscitation with Low-Titer Type O Whole Blood for Trauma Patients

  • Double-knotting Blood Storage Bag Tubing Reduces Contamination

  • Costs of Type & Screen and Crossmatch Laboratory Tests for RBCs Higher in U.S. Compared to U.K.

  • Gene Editing of HBG1 and HBG2 Promotors to Treat β-Thalassemia and Sickle Cell Disease

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley